Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.
From Emcure Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years.
- Domestic business is expected to grow in the high single-digits to low double digits, with Emcure targeting to outgrow the industry, driven by in-house R&D and strategic in-licensing.
- International markets (Europe and Canada) anticipate low-teens compounded growth, supported by strong ramp-up in products like Amphotericin B.
- Emerging markets, including ARV and non-ARV segments, are expected to grow at a healthy double-digit rate.
- Amphotericin B, recently launched in parts of Europe, offers significant growth potential across 23 countries with expected growth from next year onward.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.
- The company plans to maintain this capex intensity to support growth and capacity expansion.
- Focus on building strong in-house capacities, considered second only to innovators for certain high-volume products.
- Strategic investments include expanding manufacturing capacities at Sanand and Pune sites to service diverse markets.
- Emphasis on technology-driven R&D pipeline and collaborations, including partnerships with academia for biologics innovation.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q3 FY26 results?
Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.